🇺🇸 FDA

Drug profile · INN

gadofosveset trisodium

ABLAVAR (PREVIOUSLY VASOVIST)

FDA: approved EMA: withdrawn V08CA
US status
approved
Patents linked
0
News articles
0

Quick answer

gadofosveset trisodium (ABLAVAR (PREVIOUSLY VASOVIST)) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN gadofosveset trisodium
Brand ABLAVAR (PREVIOUSLY VASOVIST)
Route INTRAVENOUS
Formulation SOLUTION
ATC code V08CA

Frequently asked questions

What is gadofosveset trisodium?

gadofosveset trisodium (ABLAVAR (PREVIOUSLY VASOVIST)) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for gadofosveset trisodium?

ABLAVAR (PREVIOUSLY VASOVIST) is a marketed brand name for gadofosveset trisodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of gadofosveset trisodium?

gadofosveset trisodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.